A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleo-tide targeting protein kinase A R1alpha in patients with advanced solid cancers - Goel, S; Desai, K; Macapinlac, M (Invest New Drugs, 2006)